Release date: 12 April 2019
Promoter – Financial Intermediary
The project supports the Promoter's research and development (R&D) investments to progress a pipeline of new therapeutics across the pharmaceutical value-chain.
R&D investments concern pediatric-friendly therapeutics adressing critical unmet medical needs in the field of rare and orphan diseases across the pharmaceutical value-chain.
- Services - Professional, scientific and technical activities
Proposed EIB finance (Approximate amount)
EUR 20 million
Total cost (Approximate amount)
EUR 51 million
R&D investments are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an environmental impact assessment (EIA) under the Directive 2011/92/EU. Full environmental details will be verified during the appraisal.
The project promoter is a private company not operating in the utilities sector and not having the status of a contracting authority. Thus it is not covered by EU Directives on procurement. However, the Promoter's procurement procedures are expected to be in line with EIB guidelines for private sector projects. The Bank's services will verify details during the project due diligence.
Signed - 2/07/2019
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The data provided on this page is therefore indicative and cannot be considered to represent official EIB policy (see also the Explanatory notes).